Bellevue Group’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Bellevue Group’s Portfolio OXFD Stock Details OXFD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-800,157	Closed	-$14M	–	236
2020 Q4	$14M	Hold	800,157	–	–	0.16%	109
2020 Q3	$9.36M	Buy	800,157 +116,362	+17%	+$1.54M	0.13%	109
2020 Q2	$8.89M	Buy	683,795 +21,480	+3%	+$258K	0.13%	113
2020 Q1	$6.13M	Buy	662,315 +24,343	+4%	+$340K	0.12%	108
2019 Q4	$10.6M	Hold	637,972	–	–	0.17%	88
2019 Q3	$10.6M	Buy	637,972 +59,357	+10%	+$821K	0.2%	83
2019 Q2	$7.96M	Buy	578,615 +52,453	+10%	+$802K	0.14%	95
2019 Q1	$9.07M	Buy	526,162 +219,556	+72%	+$3.47M	0.5%	56
2018 Q4	$3.92M	Buy	306,606 +84,769	+38%	+$1.29M	0.26%	76
2018 Q3	$3.6M	Buy	221,837 +111,176	+100%	+$1.59M	0.23%	86
2018 Q2	$1.43M	Buy	+110,661	New	+$1.49M	0.12%	104

Bellevue Group's OXFD Position: Q1 2021 in Review

Bellevue Group sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q1 2021, closing a stake of 800,157 shares — an estimated $14M sold.

Bellevue Group first reported a position in OXFD in Q2 2018 and held it in 11 quarters. The position peaked at $14M in Q4 2020. 0 funds tracked by Wall St. Rank hold OXFD as of Q1 2021.

Bellevue Group reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q1 2021 after selling out during the quarter.
Bellevue Group sold 800,157 Oxford Immunotec Global PLC Ordinary Shares shares in Q1 2021, an estimated $14M.
Bellevue Group first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q2 2018 and held it in 11 quarters.
Bellevue Group's Oxford Immunotec Global PLC Ordinary Shares position peaked at $14M in Q4 2020.
0 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q1 2021.

Based on Bellevue Group's 13F filing for Q1 2021, filed 12 May 2021.